Carboxymethyl Chitosan Nanoparticles Loaded with Bioactive Peptide OH-CATH30 Benefit Nonscar Wound Healing
Overview
Authors
Affiliations
Background: Nonscar wound healing is a desirable treatment for cutaneous wounds worldwide. Peptide OH-CATH30 (OH30) from king cobra can selectively regulate the innate immunity and create an anti-inflammatory micro-environment which might benefit nonscar wound healing.
Purpose: To overcome the enzymatic digestion and control release of OH30, OH30 encapsulated in carboxymethyl chitosan nanoparticles (CMCS-OH30 NP) were prepared and their effects on wound healing were evaluated.
Methods: CMCS-OH30 NP were prepared by mild ionic gelation method and properties of the prepared CMCS-OH30 NP were determined by dynamic light scattering. Encapsulation efficiency, stability and release profile of OH30 from prepared CMCS-OH30 NP were determined by HPLC. Cytotoxicity, cell migration and cellular uptake of CMCS-OH30 NP were determined by conventional methods. The effects of prepared CMCS-OH30 NP on the wound healing was investigated by full-thickness excision animal models.
Results: The release of encapsulated OH30 from prepared CMCS-OH30 NP was maintained for at least 24 h in a controlled manner. CMCSOH30 NP enhanced the cell migration but had no effects on the metabolism and proliferation of keratinocytes. In the full-thickness excision animal models, the CMCS-OH30 NP treatment significantly accelerated the wound healing compared with CMCS or OH30 administration alone. Histopathological examination suggested that CMCS-OH30 NP promoted wound healing by enhancing the granulation tissue formation through the re-epithelialized and neovascularized composition. CMCS-OH30 NP induced a steady anti-inflammatory cytokine IL10 expression but downregulated the expressions of several pro-inflammatory cytokines.
Conclusion: The prepared biodegradable drug delivery system accelerates the healing and shows better prognosis because of the combined effects of OH30 released from the nanoparticles.
Cathelicidins: Opportunities and Challenges in Skin Therapeutics and Clinical Translation.
Dzurova L, Holaskova E, Pospisilova H, Schneider Rauber G, Frebortova J Antibiotics (Basel). 2025; 14(1).
PMID: 39858288 PMC: 11762488. DOI: 10.3390/antibiotics14010001.
Medical Applications and Cellular Mechanisms of Action of Carboxymethyl Chitosan Hydrogels.
Kruczkowska W, Klosinski K, Grabowska K, Galeziewska J, Gromek P, Kciuk M Molecules. 2024; 29(18).
PMID: 39339355 PMC: 11433660. DOI: 10.3390/molecules29184360.
Hou N, Chen B Pharmaceutics. 2023; 15(9).
PMID: 37765272 PMC: 10536673. DOI: 10.3390/pharmaceutics15092304.
Advanced delivery systems for peptide antibiotics.
Cesaro A, Lin S, Pardi N, de la Fuente-Nunez C Adv Drug Deliv Rev. 2023; 196:114733.
PMID: 36804008 PMC: 10771258. DOI: 10.1016/j.addr.2023.114733.
Peptide Biomaterials for Tissue Regeneration.
Ross A, Sauce-Guevara M, Alarcon E, Mendez-Rojas M Front Bioeng Biotechnol. 2022; 10:893936.
PMID: 35992354 PMC: 9388858. DOI: 10.3389/fbioe.2022.893936.